Pharmanova to commercialise MediGene's Veregen in South-eastern Europe
This article was originally published in Scrip
Executive Summary
Germany's MediGene has signed yet another agreement for its treatment for genital warts, Veregen ointment (previously Polyphenon E), the latest deal being with Serbian company, Pharmanova, which will supply and commercialise the product in South-eastern Europe. The territories covered by the agreement include Serbia, Bosnia and Herzegovina, Montenegro, Macedonia, Croatia, Slovenia, and Albania.